Background Febrile neutropenia (FN) is a common and serious complication in patients with leukemia. Hemostasis inflammation are two interrelated systems response to infection. We aimed investigate the course of thrombin formation febrile attack children acute lymphoblastic leukemia (ALL). Methods Thrombin generation was monitored treated for ALL at diagnosis (t 0 ), 48 th hour FN (t1) after rec...

Introduction: National guidelines do not support routine empiric vancomycin use in the initial management of febrile neutropenia (FN) and only recommend it patients with specific clinical indications. This bi-phasic quality improvement project aimed to evaluate current FN improve compliance a guideline-driven algorithm (GDA) ensure appropriate prescribing therapy duration community hospital.

PURPOSE Functional polymorphisms of the UGT1A1 gene, particularly the UGT1A1*28 variant, are associated with the severity of the bone marrow suppression in patients with metastatic colorectal cancer receiving irinotecan. This study assesses the cost-effectiveness of screening for UGT1A1*28 polymorphism associated with primary prophylactic Granulocytes Colony Stimulating Factor in patients homoz...

BACKGROUND Febrile neutropenia is a frequently occurring and occasionally life-threatening complication of treatment for childhood cancer. Many biomarkers have been proposed as predictors of adverse events. We aimed to undertake a systematic review and meta-analysis to summarize evidence on the discriminatory ability of initial serum biomarkers of febrile neutropenic episodes in children and yo...

The aims of this study were to i) reveal the population pharmacokinetics; and ii) assess the probability of target attainment (PTA) and cumulative fraction of response (CFR) (defined as the expected population PTA for a specific drug dose and a specific population of microorganisms) of imipenem in febrile neutropenic patients with bacteraemia. Ten patients were randomised into two groups: Group...

Cefpirome, a fourth generation cephalosporin, was administered during 154 episodes of febrile neutropenia in 106 patients. We assessed the clinical efficacy of cefpirome and its activity against isolated pathogens in neutropenic patients with hematologic malignancies. In addition, the pharmacokinetics and optimal dosing regimen of cefpirome during neutropenia were investigated.

The National Institute for Health and Care Excellence in the UK advocates that patients with neutropenia who are at low risk of developing septic complications should be considered for management in the community rather than in hospital. The Multinational Association of Supportive Care in Cancer (MASCC) risk index is widely used to identify patients who are deemed to be at low risk of developin...